Computer Model Predicts Risk for Ventricular Arrythmia in ARVC
WEDNESDAY, April 3, 2019 -- A new model can predict the risk for incident ventricular arrhythmias (VAs) in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVC), according to a study published online March 27 in the European... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 3, 2019 Category: Pharmaceuticals Source Type: news
Atrial Arrhythmias in Takotsubo Syndrome Atrial Arrhythmias in Takotsubo Syndrome
Inflammation may be a predictor for new onset atrial arrhythmias in Takotsubo cardiomyopathy.Europace (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 22, 2019 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news
ACC 2019: Medtronic, Edwards low-risk TAVR trial data could pave way to new indications
Results from trials of both Medtronic‘s (NYSE:MDT) and Edwards Lifesciences‘ (NYSE:EW) transcatheter aortic valve replacement systems exploring their use in low-risk patients indicated that the devices were as safe as open surgery, paving the way for possible new indications for TAVR technology.
Data from the trials were presented over the weekend at the American College of Cardiology 68th Annual Scientific Session 2019 in New Orleans and simultaneously published in the New England Journal of Medicine.
Currently, TAVR devices are only approved by the FDA for treating severe aortic valve stenosis in patients at inte...
Source: Mass Device - March 18, 2019 Category: Medical Devices Authors: Fink Densford Tags: Cardiac Implants Cardiovascular Clinical Trials Featured Replacement Heart Valves Edwards Lifesciences Medtronic Source Type: news
Novartis joins the Global Chagas Disease Coalition and also announces first multinational, prospective, randomized study in people with chronic Chagas cardiomyopathy
At the Annual Meeting of the Global Chagas Disease Coalition in Barcelona, Spain, Novartis announced that it is joining the Coalition as a member contributor. In addition, the company announced its commitment to launch a multinational, prospective, randomized study with heart failure drug, Entresto® (sacubitril / valsartan), in people with chronic Chagas cardiomyopathy, one form of heart failure with reduced ejection fraction. (Source: World Pharma News)
Source: World Pharma News - March 15, 2019 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news
Long - Term Cardiomyopathy Risk Varies by Chemo Agent
Decreased risk seen for daunorubicin versus doxorubicin among survivors of childhood cancer (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - March 1, 2019 Category: Cancer & Oncology Tags: Cardiology, Oncology, Pediatrics, Pharmacy, Journal, Source Type: news
